Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2012, Article ID 541650, 10 pages
http://dx.doi.org/10.1155/2012/541650
Clinical Study

Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma

1Institute of Clinical Medicine, University of Tromso, 9037 Tromso, Norway
2Department of Oncology, University Hospital of North Norway, 9038 Tromso, Norway
3Institute of Medical Biology, University of Tromso, 9037 Tromso, Norway
4Department of Pathology, University Hospital of North Norway, 9038 Tromso, Norway

Received 24 October 2011; Accepted 1 December 2011

Academic Editor: Alberto Pappo

Copyright © 2012 Eivind Smeland et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Pouysségur, F. Dayan, and N. M. Mazure, “Hypoxia signalling in cancer and approaches to enforce tumour regression,” Nature, vol. 441, no. 7092, pp. 437–443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. E. Airley, R. M. Phillips, A. E. Evans et al., “Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts,” International Journal of Oncology, vol. 26, no. 6, pp. 1477–1484, 2005. View at Google Scholar · View at Scopus
  3. M. Hockel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel, “Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix,” Cancer Research, vol. 56, no. 19, pp. 4509–4515, 1996. View at Google Scholar · View at Scopus
  4. D. M. Brizel, S. P. Scully, J. M. Harrelson et al., “Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma,” Cancer Research, vol. 56, no. 5, pp. 941–943, 1996. View at Google Scholar · View at Scopus
  5. M. Nordsmark, M. Hoyer, J. Keller, O. S. Nielsen, O. M. Jensen, and J. Overgaard, “The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas,” International Journal of Radiation Oncology Biology Physics, vol. 35, no. 4, pp. 701–708, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. L. S. Mortensen, S. Buus, M. Nordsmark et al., “Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode,” Acta Oncologica, vol. 49, no. 7, pp. 934–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kaluz, M. Kaluzová, S. Y. Liao, M. Lerman, and E. J. Stanbridge, “Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?” Biochimica et Biophysica Acta, Reviews on Cancer, vol. 1795, no. 2, pp. 162–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Vordermark and J. M. Brown, “Endogenous markers of tumor hypoxia: predictors of clinical radiation resistance?” Strahlentherapie und Onkologie, vol. 179, no. 12, pp. 801–811, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Jankovic, C. Aquino-Parsons, J. A. Raleigh et al., “Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix,” Cytometry Part B, Clinical Cytometry, vol. 70, no. 2, pp. 45–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Mayer, M. Hockel, and P. Vaupel, “Endogenous hypoxia markers: case not proven!,” Advances in Experimental Medicine and Biology, vol. 614, pp. 127–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. G. L. Semenza and G. L. Wang, “A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation,” Molecular and Cellular Biology, vol. 12, no. 12, pp. 5447–5454, 1992. View at Google Scholar · View at Scopus
  12. H. Tian, S. L. McKnight, and D. W. Russell, “Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells,” Genes and Development, vol. 11, no. 1, pp. 72–82, 1997. View at Google Scholar · View at Scopus
  13. M. Heidbreder, F. Frohlich, O. Johren, A. Dendorfer, F. Qadri, and P. Dominiak, “Hypoxia rapidly activates HIF-3alpha mRNA expression,” The FASEB Journal, vol. 17, no. 11, pp. 1541–1543, 2003. View at Google Scholar · View at Scopus
  14. Y. Z. Gu, S. M. Moran, J. B. Hogenesch, L. Wartman, and C. A. Bradfield, “Molecular characterization and chromosomal localization of a third α- class hypoxia inducible factor subunit, HIF3α,” Gene Expression, vol. 7, no. 3, pp. 205–213, 1998. View at Google Scholar · View at Scopus
  15. M. Ema, S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, and Y. Fujii-Kuriyama, “A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4273–4278, 1997. View at Google Scholar · View at Scopus
  16. H. Zhong, A. M. de Marzo, E. Laughner et al., “Overexpression of hypoxia-inducible factor 1{{α}} in common human cancers and their metastases,” Cancer Research, vol. 59, no. 22, pp. 5830–5835, 1999. View at Google Scholar · View at Scopus
  17. G. L. Semenza, “Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics,” Oncogene, vol. 29, no. 5, pp. 625–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Google Scholar · View at Scopus
  19. M. Kunkel, T. E. Reichert, P. Benz et al., “Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma,” Cancer, vol. 97, no. 4, pp. 1015–1024, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Younes, L. V. Lechago, J. R. Somoano, M. Mosharaf, and J. Lechago, “Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers,” Cancer Research, vol. 56, no. 5, pp. 1164–1167, 1996. View at Google Scholar · View at Scopus
  21. G. Cantuaria, A. Fagotti, G. Ferrandina et al., “GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy,” Cancer, vol. 92, no. 5, pp. 1144–1150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. R. S. Haber, A. Rathan, K. R. Weiser et al., “GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis,” Cancer, vol. 83, no. 1, pp. 34–40, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Younes, R. W. Brown, M. Stephenson, M. Gondo, and P. T. Cagle, “Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival,” Cancer, vol. 80, no. 6, pp. 1046–1051, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. M. C. Brahimi-Horn, J. Chiche, and J. Pouysségur, “Hypoxia and cancer,” Journal of Molecular Medicine, vol. 85, no. 12, pp. 1301–1307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Chiche, K. Ilc, J. Laferrière et al., “Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH,” Cancer Research, vol. 69, no. 1, pp. 358–368, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. G. L. Semenza, “Regulation of cancer cell metabolism by hypoxia-inducible factor 1,” Seminars in Cancer Biology, vol. 19, no. 1, pp. 12–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Y. Blay, M. von Mehren, and M. E. Blackstein, “Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors,” Cancer, vol. 116, no. 22, pp. 5126–5137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. T. K. Kilvaer, A. Valkov, S. Sorbye et al., “Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis,” PLoS One, vol. 5, no. 12, Article ID e15368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. D. M. Fletcher, “The evolving classification of soft tissue tumours: an update based on the new WHO classification,” Histopathology, vol. 48, no. 1, pp. 3–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Guillou, J. M. Coindre, F. Bonichon et al., “Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 350–362, 1997. View at Google Scholar · View at Scopus
  32. T. Donnem, S. Al-Saad, K. Al-Shibli et al., “Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer,” Clinical Cancer Research, vol. 13, no. 22, pp. 6649–6657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. I. Koukourakis, S. M. Bentzen, A. Giatromanolaki et al., “Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 727–735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. S. Choi, S. J. Kim, and D. S. Kim, “Glucose transporter-1 expression in squamous cell carcinoma of the tongue,” Cancer Research and Treatment, vol. 29, pp. 109–115, 2007. View at Google Scholar
  35. I. H. Ozbudak, K. Shilo, F. Tavora et al., “Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis,” Modern Pathology, vol. 22, no. 5, pp. 633–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Woelber, K. Kress, J. F. Kersten et al., “Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer,” BMC Cancer, vol. 11, article 12, 2011. View at Publisher · View at Google Scholar
  37. W. A. Ahrens, R. V. Ridenour III, B. L. Caron, D. V. Miller, and A. L. Folpe, “GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms,” Human Pathology, vol. 39, no. 10, pp. 1519–1526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Endo, U. Tateishi, K. Seki et al., “Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas,” Japanese Journal of Clinical Oncology, vol. 37, no. 12, pp. 955–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. U. Tateishi, U. Yamaguchi, K. Seki, T. Terauchi, Y. Arai, and T. Hasegawa, “Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 6, pp. 683–691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Nagamatsu, N. Umesaki, L. Li, and T. Tanaka, “Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas,” Oncology Reports, vol. 23, no. 4, pp. 1069–1076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Wang, Z. Li, H. Zhang et al., “HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer,” Cancer Biology and Therapy, vol. 10, no. 4, pp. 376–382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Shintani, A. Matsumine, K. Kusuzaki et al., “Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas,” Virchows Archiv, vol. 449, no. 6, pp. 673–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Yoshimura, D. K. Dhar, H. Kohno et al., “Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression,” Clinical Cancer Research, vol. 10, no. 24, pp. 8554–8560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Giatromanolaki, M. I. Koukourakis, E. Sivridis et al., “Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival,” British Journal of Cancer, vol. 85, no. 6, pp. 881–890, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. Q. F. Li, X. R. Wang, Y. W. Yang, and H. Lin, “Hypoxia upregulates hypoxia inducible factor (HIF)-3α expression in lung epithelial cells: characterization and comparison with HIF-1α,” Cell Research, vol. 16, no. 6, pp. 548–558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Uchida, F. Rossignol, M. A. Matthay et al., “Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1α and HIF-2α expression in lung epithelial cells: implication of natural antisense HIF-1α,” Journal of Biological Chemistry, vol. 279, no. 15, pp. 14871–14878, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Ishibashi, K. Nakagawa, M. Onimaru et al., “Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor/β1, and tissue factor and also cell growth and invasion activities,” Cancer Research, vol. 60, no. 22, pp. 6531–6536, 2000. View at Google Scholar · View at Scopus
  48. N. Pore, A. K. Gupta, G. J. Cerniglia et al., “Nelfinavir down-regulates hypoxia-inducible factor 1α and VEGF expression and increases tumor oxygenation: implications for radiotherapy,” Cancer Research, vol. 66, no. 18, pp. 9252–9259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Boeuf, J. V. M. G. Bovée, B. Lehner, P. C. W. Hogendoorn, and W. Richter, “Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours,” Histopathology, vol. 56, no. 5, pp. 641–651, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Woelber, V. Mueller, C. Eulenburg et al., “Serum carbonic anhydrase IX during first-line therapy of ovarian cancer,” Gynecologic Oncology, vol. 117, no. 2, pp. 183–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. B. C. Leibovich, Y. Sheinin, C. M. Lohse et al., “Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4757–4764, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Lie, N. M. Mazure, V. Hofman et al., “High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer,” British Journal of Cancer, vol. 102, no. 11, pp. 1627–1635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. A. W. Eckert, M. H. W. Lautner, A. Schütze et al., “Co-expression of Hif1α and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients,” Journal of Oral Pathology and Medicine, vol. 39, no. 4, pp. 313–317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. E. Lapi, T. F. Voller, and M. J. Welch, “Positron emission tomography imaging of hypoxia,” PET Clinics, vol. 4, pp. 39–47, 2009. View at Google Scholar
  55. Sauter, Tissue Microarrays, Springer, 2010.
  56. O. P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter, “Tissue microarray technology for high-throughput molecular profiling of cancer,” Human Molecular Genetics, vol. 10, no. 7, pp. 657–662, 2001. View at Google Scholar · View at Scopus
  57. Z. G. Dikmen, G. C. Gellert, P. Dogan et al., “In vivo and in vitro effects of a HIF-1α inhibitor, RX-0047,” Journal of Cellular Biochemistry, vol. 104, no. 3, pp. 985–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. G. L. Semenza, “Evaluation of HIF-1 inhibitors as anticancer agents,” Drug Discovery Today, vol. 12, no. 19-20, pp. 853–859, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Thiry, J. M. Dogne, B. Masereel, and C. T. Supuran, “Targeting tumor-associated carbonic anhydrase IX in cancer therapy,” Trends in Pharmacological Sciences, vol. 27, no. 11, pp. 566–573, 2006. View at Publisher · View at Google Scholar · View at Scopus